Arvinas
PROTAC pioneer whose vepdegestrant became the first approved targeted protein degrader in 2026.
Vepdegestrant (ER, with Pfizer), ARV-393 (BCL6), ARV-102 (LRRK2, neurology); founded on Craig Crews' PROTAC technology.
Pages like this
not linked directly; found by shared links- Key paperThe first PROTAC: a chimeric molecule that tags a protein for destruction
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- CompanyKymera Therapeutics
Shares An open degrader consortium against every undruggable driver transcription factor, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers, HR-positive / HER2-negative breast cancer.
- IdeaDegrade the damaged p53 protein rather than trying to repair it
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- CompanyMonte Rosa Therapeutics
Shares An open degrader consortium against every undruggable driver transcription factor, PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- TrialVERITAC-2
Shares Vepdegestrant, HR-positive / HER2-negative breast cancer.
- IdeaDrag cancer's surface and secreted proteins to the cell's recycling bin
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaInstruct tumour cells to make antibodies against their own oncoprotein
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.
- IdeaFind E3 ligases that only tumours have, and build degraders around them
Shares PROTACs & molecular glues (targeted protein degradation), The undruggable drivers.